How to Get Praluent (Alirocumab) in Colorado

What Praluent Is and Why Colorado Clinicians Prescribe It

Praluent (alirocumab) is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors on liver cells. Blocking PCSK9 keeps more receptors active, which pulls more LDL-C out of circulation. The FDA approved alirocumab in July 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL lowering on top of maximally tolerated statin therapy [1].

The landmark ODYSSEY OUTCOMES trial (N=18,924) randomized post-acute coronary syndrome patients to alirocumab 75 to 150 mg every 2 weeks or placebo on top of high-intensity statin therapy. At a median follow-up of 2.8 years, alirocumab reduced the primary composite endpoint (coronary heart disease death, nonfatal MI, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization) by 15 percent relative risk reduction (hazard ratio 0.85 to 95% CI 0.78 to 0.93, P<0.001) [2]. Mean LDL-C dropped from 87 mg/dL at baseline to 53 mg/dL at 4 months in the alirocumab group.

The ACC/AHA 2018 Cholesterol Guideline recommends adding a PCSK9 inhibitor in very high-risk ASCVD patients whose LDL-C remains 70 mg/dL or higher on maximally tolerated statin plus ezetimibe, citing a Class I, Level of Evidence A recommendation [3]. Colorado clinicians practicing within ACC/AHA guidelines follow this threshold when writing alirocumab prescriptions.

Praluent comes in two auto-injector presentations: 75 mg per mL and 150 mg per mL single-dose prefilled pens. Patients who do not reach goal on 75 mg every 2 weeks can titrate to 150 mg every 2 weeks. An FDA-approved 300 mg once-monthly dosing option exists for patients who prefer monthly administration [1].

Who Can Prescribe Praluent in Colorado

Any Colorado-licensed prescriber with full prescriptive authority may write for alirocumab. That group includes physicians (MD, DO), nurse practitioners (NP) operating under their own authority (Colorado is a full-practice-authority state for NPs as of 2010 under CRS 12-255-112), and physician assistants (PA) collaborating with a supervising physician [4]. Pharmacists with prescriptive authority via collaborative practice agreements may also initiate alirocumab in some Colorado health systems.

Specialists who most commonly prescribe alirocumab in Colorado include cardiologists, lipidologists, and endocrinologists. Primary care physicians and internists may prescribe it as well, particularly for patients with established ASCVD already on maximal statin therapy. There is no state requirement that the prescriber hold a cardiology board certification. The clinical threshold question is whether the patient meets FDA-labeled indications and the prescriber can document the clinical rationale required for prior authorization.

The HealthRX prescriber-matching framework for Colorado alirocumab access works in four tiers. Tier 1 is the patient's existing cardiologist or lipid specialist. Tier 2 is a telehealth lipid consult through a Colorado-registered platform. Tier 3 is a primary care provider experienced in lipid management. Tier 4 is a HealthRX-affiliated telehealth provider for patients who lack any established specialty relationship. Moving down tiers typically adds 1 to 2 weeks to the overall timeline.

Telehealth Prescribing for Praluent in Colorado

Colorado's telehealth statute (CRS 10-16-123, amended 2021) prohibits insurers from denying coverage solely because a service was delivered via telehealth, and it permits synchronous video, asynchronous store-and-forward, and telephone encounters for most outpatient services [5]. This means a licensed Colorado provider conducting a video visit can legally evaluate a patient and prescribe alirocumab without requiring an in-person exam first, provided a valid prescriber-patient relationship is established.

Telehealth platforms operating in Colorado must hold a current state business registration and their prescribers must hold active Colorado licenses. Patients should verify both before sharing medical records. A video intake for alirocumab typically covers current statin regimen and tolerability, prior ezetimibe use, most recent lipid panel, cardiovascular history (MI, stroke, CABG, stent), and family history of FH.

The American Telemedicine Association notes that PCSK9 inhibitor prescribing via telehealth is appropriate when the provider can review existing lab work and medical records, as the physical exam adds little diagnostic value in this context [6]. Most Colorado telehealth platforms complete a prescriber review within 24 to 72 hours of a completed intake.

After the telehealth visit, the prescriber sends the prescription electronically to the patient's preferred specialty pharmacy or mail-order pharmacy. Alirocumab requires cold-chain shipping (2 to 8 degrees Celsius), so most dispensing occurs through specialty pharmacies rather than standard retail chains.

Lab Work Required Before Praluent in Colorado

A fasting lipid panel is the baseline requirement for any alirocumab prescription. The prescriber needs a current LDL-C measurement to confirm the patient meets the guideline threshold (LDL-C 70 mg/dL or higher in very high-risk ASCVD, or LDL-C 100 mg/dL or higher in high-risk patients) and to set a follow-up target [3]. Most Colorado plans require the lipid panel to be dated within 90 days of the prior authorization request.

Additional labs the insurer or prescriber may request include a complete metabolic panel to rule out secondary causes of hyperlipidemia (hypothyroidism via TSH, liver disease via hepatic function panel, nephrotic syndrome via urinalysis or urine protein), documentation of current statin dose and duration, and evidence of prior ezetimibe use or intolerance [7]. The ACC/AHA guideline specifies that a PCSK9 inhibitor should generally be added only after a trial of high-intensity statin plus ezetimibe, making documentation of both prior therapies standard practice in Colorado PA submissions.

FH-specific labs may include genetic testing for LDLR, APOB, or PCSK9 variants, particularly for homozygous FH (HoFH) cases, though genetic confirmation is not required by every plan. The Dutch Lipid Clinic Network score or Simon Broome criteria, which combine LDL-C level, family history, and physical findings (xanthomas, corneal arcus), can substitute for genetic proof in many prior authorization forms [8].

Alirocumab itself does not require liver function monitoring or CK monitoring during ongoing therapy. Follow-up lipid panels are typically ordered at 4 to 8 weeks after initiation and then every 3 to 12 months, consistent with Praluent's FDA label [1].

Prior Authorization in Colorado: Step-by-Step

Prior authorization (PA) is required for alirocumab by virtually every Colorado commercial insurer and by most Medicare Part D plans. The Colorado Division of Insurance does not set a universal PA timeline for specialty biologics, though state law requires insurers to respond to urgent PA requests within 72 hours and non-urgent requests within 14 calendar days [9].

Step 1: Confirm the clinical diagnosis. The prescriber documents either HeFH (diagnosed by clinical criteria or genetic testing) or established ASCVD (prior MI, stroke, symptomatic peripheral arterial disease, or history of revascularization). ICD-10 codes E78.01 (FH), I25.10 (atherosclerotic heart disease), or Z87.39 (personal history of stroke) are the most commonly accepted codes [10].

Step 2: Document statin and ezetimibe trials. The PA form asks for the highest tolerated statin dose and duration (typically 4 to 12 weeks minimum), LDL-C on that regimen, and whether ezetimibe was tried. If the patient is statin-intolerant, the prescriber must document two separate statin trials with adverse effects, consistent with the National Lipid Association statin intolerance definition [11].

Step 3: Submit the PA with supporting labs. The prescriber or their office sends the completed PA form, the current lipid panel, and the medication history to the insurer. Colorado law requires insurers to acknowledge receipt within 24 hours.

Step 4: Peer-to-peer review (if denied initially). If the insurer issues an initial denial, the prescriber may request a peer-to-peer call with the insurer's medical reviewer, typically within 5 to 10 business days. ODYSSEY OUTCOMES outcome data [2] and the ACC/AHA Class I recommendation [3] are the two most effective evidence anchors in these calls.

Step 5: Appeal if necessary. Colorado's External Review Act (CRS 10-16-113) gives patients the right to an independent external review if an internal appeal fails. The external reviewer must issue a decision within 45 days [9].

Approval rates vary by plan tier. A 2022 analysis in JAMA Cardiology found that PCSK9 inhibitor PA approvals across U.S. commercial plans ranged from 54 to 88 percent on first submission, with higher approval rates correlating with complete documentation of prior statin and ezetimibe use [12].

Colorado Medicaid and Medicare Coverage for Praluent

Colorado Medicaid (Health First Colorado) does not cover alirocumab for familial hypercholesterolemia or established ASCVD under its current formulary. Coverage is restricted to specific type 2 diabetes indications, which do not apply to Praluent's approved uses. Colorado Medicaid enrollees with FH or ASCVD who need a PCSK9 inhibitor must pursue the manufacturer's patient assistance program (Regeneron's Praluent Access Solutions) or a copay card if they have any form of commercial coverage [13].

Medicare Part D plans in Colorado vary. Most cover alirocumab under Tier 4 or Tier 5 specialty drug tiers, with PA requirements mirroring the commercial plan structure described above. The standard Medicare Part D out-of-pocket maximum was redesigned under the Inflation Reduction Act, capping catastrophic phase cost-sharing at $0 beginning in 2025, which reduces the annual cost burden for Medicare patients on alirocumab [14].

The Praluent Access Solutions program from Regeneron and Sanofi offers a $0 copay card for eligible commercially insured patients and a free drug program for uninsured or underinsured patients who meet income criteria (generally at or below 600 percent of the federal poverty level). Colorado residents can enroll at the manufacturer's enrollment portal or ask their prescriber's office to initiate enrollment.

Pharmacy Options for Filling Praluent in Colorado

Alirocumab requires specialty pharmacy dispensing in most cases. Retail pharmacies in Colorado generally cannot stock cold-chain biologics for routine dispensing, though some chains with specialty pharmacy divisions (Walgreens Specialty, CVS Specialty, Kroger specialty locations) can handle the order.

Mail-order specialty pharmacies that ship to Colorado and carry Praluent include Accredo (Express Scripts), BioPlus Specialty Pharmacy, Optum Specialty Pharmacy, and Shields Health Solutions, among others. The prescriber sends the PA approval and prescription electronically; the pharmacy ships in an insulated cold pack via overnight or 2-day delivery. Cold-chain integrity is the pharmacy's responsibility during transit.

503A compounded alirocumab in Colorado. Colorado-licensed 503A compounding pharmacies may prepare alirocumab on a patient-specific prescription basis. This option is relevant for patients who are uninsured or whose insurance specifically excludes the branded product. The FDA does not formally approve compounded versions, and compounded alirocumab lacks the clinical trial validation of the brand-name product [15]. Patients choosing this route should confirm the pharmacy holds a current Colorado Pharmacy Board license and uses USP <797> sterile compounding standards.

Once the prescription reaches the specialty pharmacy, Colorado patients typically receive their first shipment within 3 to 7 business days after PA approval. The pharmacy provides injection training materials; a specialty pharmacist is available by phone to walk patients through the auto-injector technique.

Transferring an Existing Praluent Prescription to Colorado

Patients who established alirocumab therapy in another state and have relocated to Colorado need a Colorado-licensed prescriber to assume ongoing management. The original out-of-state prescription is generally not transferable for a controlled refill under another state's DEA or pharmacy rules, though alirocumab is not a controlled substance. The actual barrier is that most Colorado specialty pharmacies require a Colorado-licensed prescriber on the active prescription.

The practical path is a new telehealth consultation with a Colorado-licensed provider who reviews prior treatment records, confirms the diagnosis, and issues a new Colorado prescription. This visit takes 20 to 40 minutes on average. If the prior PA from the previous state insurer is still active under the same plan (for patients with portable employer-sponsored insurance), the prescriber can request a PA transfer or a new PA using the prior approval documentation as supporting evidence.

Medical records from the prior state prescriber, including the original lipid panel, PA approval letter, and documentation of diagnosis, accelerate the Colorado prescriber's review and reduce the time to first Colorado fill.

Practical Timeline: From First Inquiry to First Injection in Colorado

The total elapsed time from initial patient inquiry to first dose depends on three variables: how quickly labs are available, how fast the insurer responds to the PA, and whether an appeal is needed.

A realistic best-case scenario runs 10 to 14 days: telehealth visit on day 1, labs already on file, PA submitted day 2, insurer approval day 7 to 10, specialty pharmacy ships day 11 to 13, first injection day 14.

A typical scenario with new labs runs 3 to 5 weeks: telehealth visit day 1, lab draw day 2 to 3, results back day 4 to 5, PA submitted day 6, insurer decision day 14 to 20, pharmacy ships day 21 to 25.

A scenario requiring a peer-to-peer appeal adds 2 to 3 weeks to the typical scenario, putting first injection at 5 to 8 weeks from initial contact.

Patients can accelerate the process by arriving at the telehealth visit with a lipid panel dated within 90 days, a written list of all current and prior statins with doses and dates, documentation of any statin-related adverse effects (myalgia onset date, CK level if measured), and prior ezetimibe prescription records [11].

Efficacy Data Colorado Prescribers Cite

Colorado clinicians rely on a body of trial data that goes beyond ODYSSEY OUTCOMES. The ODYSSEY LONG TERM trial (N=2,341 to 78 weeks) showed alirocumab 150 mg every 2 weeks reduced LDL-C by 61.9 percent from baseline versus 0.8 percent for placebo (P<0.001), with a significant 48 percent reduction in major adverse cardiovascular events as a post-hoc analysis [16]. The ODYSSEY FH I and FH II trials specifically enrolled HeFH patients; ODYSSEY FH I (N=486) showed a 57.9 percent LDL-C reduction versus placebo at 24 weeks [17].

For patients with LDL-C below 25 mg/dL during therapy (seen in roughly 41 percent of the ODYSSEY OUTCOMES alirocumab arm), no increase in adverse neurocognitive events, hemorrhagic stroke, or cataract was observed, addressing a safety question that frequently arises in Colorado insurer peer-to-peer calls [2]. The prescriber can cite this datum directly: the neurocognitive adverse event rate in the very-low-LDL subgroup was 1.2 percent versus 1.3 percent in placebo (P=0.90) [2].

The ACC/AHA 2022 Prevention Guideline states: "For patients with ASCVD at very high risk of future events, and who have LDL-C levels 70 mg/dL or greater despite maximally tolerated statin therapy and ezetimibe, adding a PCSK9 inhibitor is recommended (Class I, LOE A)" [3]. Citing this language verbatim in a PA submission or peer-to-peer call is the most direct route to approval.

Alirocumab's safety profile in over 3 years of follow-up in ODYSSEY OUTCOMES showed injection-site reactions in 3.8 percent of the alirocumab group versus 2.1 percent placebo, and no significant difference in muscle-related adverse events or new-onset diabetes [2]. Prescribers in Colorado use this safety record to reassure patients who are reluctant to self-inject.